on Vogenx, Inc. (NASDAQ:VOGX)
Vogenx Appoints Richard Gorman as Chief Commercial Officer
Vogenx, Inc. (Nasdaq: VOGX), a company focused on developing treatments for metabolic and gastrointestinal diseases, has appointed Richard Gorman as Chief Commercial Officer, effective October 12, 2026. Gorman, who served on the board since 2022, will resign from his board position. The company plans to find a new independent director shortly.
In his new role, Gorman will spearhead Vogenx's commercial operations and corporate strategy, focusing on market development for post-bariatric hypoglycemia and gastroparesis. Gorman's responsibilities will also include business development, such as partnership and licensing strategies.
CEO James Green highlighted Gorman's significant influence on Vogenx's strategic direction since 2022, emphasizing the need for commercial strategies to advance mizagliflozin's development. With over 30 years of experience, Gorman's vast expertise includes numerous successful product launches, notably in the metabolic disease sector.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Vogenx, Inc. news